Article
Oncology
Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont
Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Roberto Cirocchi, Giulio Metaj, Michela Cicoletti, Fabrizio Arcangeli, Angelo De Sol, Giulia Poli, Paolo Bruzzone, Sara Gioia, Christos Anagnostou, Fabio Loreti, Simona Francesconi, Linda Ricci, Maria Elena Laurenti, Andrea Capotorti, Marco Artico, Vito D'Andrea, Brandon Michael Henry, Piergiorgio Fedeli, Luigi Carlini
Summary: Studies have shown significant heterogeneity in lymphatic drainage patterns of different cutaneous melanomas, emphasizing the need for multiple imaging evaluations in critical skin areas. The use of fluorescence lymphography with indocyanine green has greatly improved visualization at a microscopic level. It is crucial to combine SPET-CT scans with lymphoscintigraphy preoperatively and perform additional evaluations with indocyanine green intraoperatively to accurately identify sentinel nodes and reduce false negative rates.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Steven Morrison, Dale Han
Summary: Sentinel lymph node biopsy is crucial in the management of melanoma patients, providing important prognostic data and treatment options for various subtypes. Technological advances have improved the therapeutic potential of SLNB, while the management of patients with a positive SLN has evolved with new treatment options available.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Antonio Tejera-Vaquerizo, Aram Boada, Simone Ribero, Susana Puig, Sabela Paradela, David Moreno-Ramirez, Javier Canueto, Blanca de Unamuno-Bustos, Ana Brinca, Miguel A. Descalzo-Gallego, Simona Osella-Abate, Paola Cassoni, Sebastian Podlipnik, Cristina Carrera, Sergi Vidal-Sicart, Ramon Pigem, Agusti Toll, Ramon Rull, Llucia Alos, Celia Requena, Isidro Bolumar, Victor Traves, Angel Pla, Almudena Fernandez-Orland, Ane Jaka, Maria Teresa Fernandez-Figueras, Nina Anika Richarz, Ricardo Vieira, Rafael Botella-Estrada, Concepcion Roman-Curto, Lara Ferrandiz-Pulido, Nicolas Iglesias-Pena, Carlos Ferrandiz, Josep Malvehy, Pietro Quaglino, Eduardo Nagore
Summary: This study found that SLNB does not improve MSS, DFS, or OS in patients with thin melanoma. However, there is a significant difference in MSS, DFS, and OS between SLN-positive and -negative patients, confirming the value of SLNB as a prognostic procedure.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Hanna Kakish, Trisha Lal, Jason E. Thuener, Jeremy S. Bordeaux, Ankit Mangla, Luke D. Rothermel, Richard S. Hoehn
Summary: This study evaluated the utility and prognostic value of sentinel lymph node biopsy (SLNB) in lentigo maligna melanoma (LMM) using large databases. The results showed that SLNB was associated with improved overall survival (OS) but not melanoma-specific survival (MSS) in LMM patients.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Surgery
Tea Stuart Williams, Ben Tallon, Brandon Michael Adams
Summary: The controversy over whether completion lymph node dissection (CLND) should be performed following a positive sentinel lymph node biopsy (SLNB) remains. This study suggests that for a high-risk population with larger metastatic deposits in sentinel lymph nodes and higher rates of non-sentinel node involvement, forgoing CLND in the context of a positive SLNB may put patients at risk.
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY
(2022)
Article
Oncology
Raghav Tripathi, Karen Larson, Graham Fowler, Dale Han, John T. Vetto, Jeremy S. Bordeaux, Wesley Y. Yu
Summary: This study developed and validated a personalized clinical decision-making tool (ELMO) using nationally representative data to predict lymphatic metastasis in melanoma patients. The tool showed high accuracy and sensitivity in predicting sentinel lymph node biopsy status and could reduce unnecessary procedures. It was externally validated at a large tertiary referral center.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Elena Parvez, Farzin Khosrow-Khavar, Teodora Dumitra, Carolyn Nessim, Ericka Bernard-Bedard, Justin Rivard, Vera Pravong, Sara Wang, Mai-Kim Gervais, Sarkis Meterissian, Sinziana Dumitra
Summary: This study examines real-world practices and outcomes of patients with melanoma sentinel lymph node metastases after the publication of the MSLT-II trial. The findings suggest that although practice patterns have changed, completion lymphadenectomy (CLND) does not reduce the risk of recurrence or mortality.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Che-Chia Hsu, Yi-Hua Liao, Yi-Shuan Sheen
Summary: A retrospective study in Taiwan found that sentinel lymph node biopsy (SLNB) offers survival benefits over nodal observation in early-stage melanoma patients. Among 227 patients who met the SLNB criteria, survival analysis showed significantly improved melanoma-specific survival in the SLNB group. Immediate completion lymph node dissection resulted in significantly longer melanoma-specific survival and distant-metastasis-free survival compared to nodal observation.
PIGMENT CELL & MELANOMA RESEARCH
(2023)
Article
Dermatology
Adrienne B. Shannon, Cimarron E. Sharon, Richard J. Straker, Michael J. Carr, Andrew J. Sinnamon, Kita Bogatch, Alexandra Thaler, Nicholas Kelly, John T. Vetto, Graham Fowler, Danielle DePalo, Vernon K. Sondak, John T. Miura, Mark B. Faries, Edmund K. Bartlett, Jonathan S. Zager, Giorgos C. Karakousis
Summary: Sentinel lymph node biopsy is not routinely recommended for T1a cutaneous melanoma due to low risk of positivity. This study identified age, primary tumor location, lymphovascular invasion, and mitotic rate as factors associated with positive sentinel lymph node in T1a melanoma patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Oncology
Michael J. Carr, Federico A. Monzon, Jonathan S. Zager
Summary: The necessity and application of sentinel lymph node biopsy in patients with primary tumors of different thicknesses remain controversial, with decisions left to patients and treating physicians. Recent studies have focused on predicting SLN positivity, providing valuable insights for improving physicians' predictive abilities.
CLINICAL & EXPERIMENTAL METASTASIS
(2022)
Article
Oncology
Stacy B. Sanders, Tanya L. Hoskin, Arielle P. Stafford, Judy C. Boughey
Summary: This study evaluated the rate of non-sentinel lymph node (NSLN) positivity and factors influencing this in patients with a positive sentinel lymph node (SLN) following neoadjuvant chemotherapy (NAC). The results showed a high rate of nodal positivity on completion axillary lymph node dissection (cALND) in the setting of positive SLN after NAC, supporting the current standard of routine cALND. In patients with cN+ disease, NSLN positivity varied based on tumor biology, multicentricity/multifocality, number of positive SLNs, and SLN metastasis size.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Ilaria Mattavelli, Andrea Maurichi, Carlotta Galeone, Gianfranco Gallino, Consuelo Barbieri, Andrea Leva, Elena Tolomio, Barbara Valeri, Mara Cossa, Roberto Patuzzo, Mario Santinami
Summary: This study evaluated the role of SNB in melanoma patients who developed first loco-regional recurrence. The SN positivity rate in patients with LR or IT was significantly higher than in primary tumors. Additionally, DFS was slightly higher in SN negative patients, but without statistically significant differences.
Article
Oncology
Joshua N. Herb, David W. Ollila, Karyn B. Stitzenberg, Michael O. Meyers
Summary: The study estimated the use of SLNB, positivity prevalence, and procedural costs in patients with non-ulcerated T1b melanoma using a population-based registry. Results showed that only 4% of patients had a positive SLNB, lower than previous reports, and factors such as age, mitosis rate, sex, and tumor location were associated with positivity. The study highlighted the high costs per prognostic information gained with SLNB at the population level.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Ophthalmology
Pau Cid-Bertomeu, Valentin Huerva
Summary: Primary acquired melanosis (PAM) is a conjunctival pigmentation that can lead to conjunctival melanoma (CM). Surgical excision is the preferred treatment, but topical chemotherapy with interferon alpha 2b (IFN-a2b) is also an important option. IFN-a2b has shown efficacy in treating PAM and CM, with low toxicity.
SURVEY OF OPHTHALMOLOGY
(2022)